{"id":43254,"date":"2025-10-14T15:16:03","date_gmt":"2025-10-14T07:16:03","guid":{"rendered":"https:\/\/flcube.com\/?p=43254"},"modified":"2025-10-14T15:16:04","modified_gmt":"2025-10-14T07:16:04","slug":"gsk-receives-china-nmpa-approval-for-shingrix-in-immunocompromised-adults","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43254","title":{"rendered":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE:\u202fGSK<\/a>)<\/strong> announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for <strong>Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell)<\/strong> to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-key-facts\">Key Facts<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Vaccine<\/strong><\/td><td>Shingrix\u00ae (recombinant subunit, glycoprotein\u202fE + AS01B adjuvant)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>China NMPA for adults\u202f\u2265\u202f18\u202fyrs with immunocompromise<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of herpes zoster (shingles)<\/td><\/tr><tr><td><strong>Global Context<\/strong><\/td><td>Approved worldwide for adults\u202f\u2265\u202f50\u202fyrs; expanding to younger high\u2011risk adults in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-why-shingrix-matters\">Why Shingrix Matters<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011Live, Recombinant Platform<\/strong> \u2013 Eliminates risk of vaccine\u2011associated disease in immunocompromised patients.<\/li>\n\n\n\n<li><strong>AS01B Adjuvant<\/strong> \u2013 Boosts immunogenicity, counteracting age\u2011related immune decline.<\/li>\n\n\n\n<li><strong>Broad Coverage<\/strong> \u2013 Protects high\u2011risk groups, including transplant recipients and patients on immunosuppressive therapy.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-impact-for-china\">Impact for China<\/h4>\n\n\n\n<p>China\u2019s NMPA approval expands Shingrix\u2019s reach to a critical segment of the population\u2014immunocompromised adults who are most vulnerable to zoster reactivation. GSK will work with local partners to scale distribution and ensure timely access for eligible patients.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-about-glaxosmithkline\">About GlaxoSmithKline<\/h4>\n\n\n\n<p>GlaxoSmithKline (GSK) is a global research\u2011driven pharmaceutical company focused on improving health through innovative medicines, vaccines, and consumer healthcare products. The company\u2019s vaccine portfolio includes several life\u2011saving immunizations, with Shingrix\u00ae among its flagship products for viral disease prevention.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43255,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15,12],"class_list":["post-43254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43254\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43254\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T07:16:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T07:16:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults\",\"datePublished\":\"2025-10-14T07:16:03+00:00\",\"dateModified\":\"2025-10-14T07:16:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1406.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43254#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43254\",\"name\":\"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1406.webp\",\"datePublished\":\"2025-10-14T07:16:03+00:00\",\"dateModified\":\"2025-10-14T07:16:04+00:00\",\"description\":\"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43254\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1406.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43254#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43254","og_locale":"en_US","og_type":"article","og_title":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults","og_description":"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.","og_url":"https:\/\/flcube.com\/?p=43254","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-14T07:16:03+00:00","article_modified_time":"2025-10-14T07:16:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43254#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43254"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults","datePublished":"2025-10-14T07:16:03+00:00","dateModified":"2025-10-14T07:16:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43254"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43254#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43254#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43254","url":"https:\/\/flcube.com\/?p=43254","name":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43254#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43254#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","datePublished":"2025-10-14T07:16:03+00:00","dateModified":"2025-10-14T07:16:04+00:00","description":"GlaxoSmithKline (NYSE:\u202fGSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix\u00ae (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18\u202fyears and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43254#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43254"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43254#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","width":1080,"height":608,"caption":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43254#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43254"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43254\/revisions"}],"predecessor-version":[{"id":43256,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43254\/revisions\/43256"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43255"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}